On February 18, 2017 Percans Oncology reported to developing and promoting susceptibility testing technologies of anti-tumor drugs with high clinical predictivity, and assisting clinicians with the best plan for individualized tumor treatment (Press release, Cothera Bioscience, FEB 18, 2017, View Source [SID1234618856]). Recently, Fortune United Partners invested in Beijing Percans Oncology Co., Ltd. as the leading investor in series-B financing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Established in 2012, Beijing Percans Oncology Co., Ltd. is a service company focusing on individualized tumor treatment. Through strategic cooperation with top international and domestic cancer medical centers, Percans Oncology seeks the best chemotherapy plan for postoperative tumor patients, so as to improve the effectiveness of clinical chemotherapy and maximize the survival time of patients, and promote the development of anti-tumor drug research.
The third-generation drug susceptibility testing technology, corresponding more closely to clinical applications
The new third-generation drug susceptibility testing technology i-Chemo, based on technologies such as "micro-tumor", not only continues the accuracy of predicting clinical drug response, but also greatly shortens the testing cycle and cuts the cost. The most effective treatment plan can be accurately determined among a variety of clinical drug plans within 9 days to avoid ineffective treatments.
This pioneering work can help clinicians find the most suitable medication plan for cancer patients within the best treatment period, thus enriched the connotation of precision medicine and will have a wide range of potential applications in the future. At present, Percans Oncology is working with more tumor hospitals to carry out clinical research on i-Chemo drug susceptibility testing, and further promoting related research and application in this field.
Relying on the professional teams in medicine, scientific research, product development and marketing, as well as powerful cancer drug screening technologies and highly efficient bench-to-bedside translation ability in oncological research, Percans Oncology is devoted to serve cancer patients in China and worldwide.